The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).
 
Marwan Fakih
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche
Speakers' Bureau - Amgen; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
 
Greg Andrew Durm
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
 
Ramaswamy Govindan
Honoraria - Abbvie; Genentech/Abbvie; Geneplus
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech/Roche; GlaxoSmithKline; Ignyta; Janssen; Jounce Therapeutics; Lilly; Merck Serono; Nektar; Pfizer; Phillips Gilmore Oncology; Roche
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BeiGene (Inst); Bioatla (Inst); Biothera (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Exelixis (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); poseida therapeutics (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute
 
Neelesh Soman
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Haby Adel Henary
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena; Presagia
Consulting or Advisory Role - Alphasights; Axiom Biotechnologies; Bayer; Genentech; Gerson Lehrman Group; GroupH; Guidepoint Global; Infinity Pharmaceuticals; Medscape; Merrimack; Numab; Pfizer; PrimE Oncology; Seagen; Takeda; Trieza Therapeutics; WebMD
Research Funding - Abbvie; Adaptimmune; Aldai Norte; Amgen; AstraZeneca/MedImmune; Bayer; Daiichi Sankyo; Fate Therapeutics; Genentech; Infinity Pharmaceuticals; Kite, a Gilead company; Kura Oncology; MedImmune; Mirati Therapeutics; Molecular Templates; National Cancer Institute; Pfizer; Seagen; Shattuck Labs; TCR2 Therapeutics; TP Therapeutics
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer